Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 121.96 million. The enterprise value is 144.61 million.
Market Cap | 121.96M |
Enterprise Value | 144.61M |
Important Dates
The last earnings date was Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lavipharm has 168.69 million shares outstanding. The number of shares has increased by 73.56% in one year.
Current Share Class | n/a |
Shares Outstanding | 168.69M |
Shares Change (YoY) | +73.56% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.51% |
Owned by Institutions (%) | 3.46% |
Float | 64.01M |
Valuation Ratios
The trailing PE ratio is 17.09.
PE Ratio | 17.09 |
Forward PE | n/a |
PS Ratio | 2.36 |
PB Ratio | 2.37 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.50, with an EV/FCF ratio of -36.56.
EV / Earnings | 19.55 |
EV / Sales | 2.82 |
EV / EBITDA | 18.50 |
EV / EBIT | 40.44 |
EV / FCF | -36.56 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.61.
Current Ratio | 1.24 |
Quick Ratio | 0.62 |
Debt / Equity | 0.61 |
Debt / EBITDA | 4.01 |
Debt / FCF | -7.92 |
Interest Coverage | 1.63 |
Financial Efficiency
Return on equity (ROE) is 15.20% and return on invested capital (ROIC) is 2.78%.
Return on Equity (ROE) | 15.20% |
Return on Assets (ROA) | 1.85% |
Return on Capital (ROIC) | 2.78% |
Revenue Per Employee | 171,147 |
Profits Per Employee | 24,653 |
Employee Count | 307 |
Asset Turnover | 0.43 |
Inventory Turnover | 1.60 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.70% in the last 52 weeks. The beta is 0.88, so Lavipharm's price volatility has been lower than the market average.
Beta (5Y) | 0.88 |
52-Week Price Change | +5.70% |
50-Day Moving Average | 0.78 |
200-Day Moving Average | 0.85 |
Relative Strength Index (RSI) | 37.13 |
Average Volume (20 Days) | 54,851 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 51.34 million and earned 7.40 million in profits. Earnings per share was 0.04.
Revenue | 51.34M |
Gross Profit | 23.25M |
Operating Income | 3.58M |
Pretax Income | 2.76M |
Net Income | 7.40M |
EBITDA | 7.11M |
EBIT | 3.58M |
Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has 8.69 million in cash and 31.31 million in debt, giving a net cash position of -22.62 million or -0.13 per share.
Cash & Cash Equivalents | 8.69M |
Total Debt | 31.31M |
Net Cash | -22.62M |
Net Cash Per Share | -0.13 |
Equity (Book Value) | 51.18M |
Book Value Per Share | 0.30 |
Working Capital | 9.20M |
Cash Flow
In the last 12 months, operating cash flow was 2.35 million and capital expenditures -6.30 million, giving a free cash flow of -3.96 million.
Operating Cash Flow | 2.35M |
Capital Expenditures | -6.30M |
Free Cash Flow | -3.96M |
FCF Per Share | -0.02 |
Margins
Gross margin is 45.27%, with operating and profit margins of 6.96% and 14.40%.
Gross Margin | 45.27% |
Operating Margin | 6.96% |
Pretax Margin | 5.38% |
Profit Margin | 14.40% |
EBITDA Margin | 13.84% |
EBIT Margin | 6.96% |
FCF Margin | -7.70% |
Dividends & Yields
Lavipharm does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -73.56% |
Shareholder Yield | -73.56% |
Earnings Yield | 6.07% |
FCF Yield | -3.24% |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
Last Split Date | Aug 1, 2022 |
Split Type | Reverse |
Split Ratio | 0.3333333333 |
Scores
Lavipharm has an Altman Z-Score of 1.41. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.41 |
Piotroski F-Score | n/a |